

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 May 2024 (23.05.2024)



(10) International Publication Number
WO 2024/104290 A1

- (51) **International Patent Classification:**
A61K 31/4545 (2006.01) *A61P 37/00* (2006.01)
- (21) **International Application Number:**
PCT/CN2023/131279
- (22) **International Filing Date:**
13 November 2023 (13.11.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/384274 18 November 2022 (18.11.2022) US
- (71) **Applicant:** **BEIJING INNOCARE PHARMA TECH CO., LTD.** [CN/CN]; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN).
- (72) **Inventors:** **CUI, Jisong**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN). **ZHAO, Renbin**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN). **ZHOU, Carrie**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN). **LIU, Ruiqin**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN). **ZHANG, Bin**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN).

(74) **Agent:** **INTELIGHT IP LAW FIRM**; Suite 1710, Tower B, Techart Plaza, No. 30 Xueyuan Road, Haidian District, Beijing 100083 (CN).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(54) **Title:** METHOD FOR TREATING MULTIPLE SCLEROSIS

Adjusted Mean Cumulative number of New Gd+ T1 Brain Lesions by Visit (N=115)




FIG. 3

(57) **Abstract:** Provided herein is a method for treating multiple sclerosis by orally administering to a subject in need thereof at least 20 mg/day, preferably 50-100 mg/day of orelabrutinib. The method is particularly effective to treat relapsing-remitting multiple sclerosis.

WO 2024/104290 A1